2-((2S,5S,8S,11S,14S,17R)-2,8-bis(4-aminobutyl)-11-(4-guanidinobutyl)-17-(hydroxymethyl)-14-isobutyl-3,6,9,12,15,19-hexaoxo-1,4,7,10,13,16-hexaazacyclononadecan-5-yl)acetic acid

ID: ALA3827091

Chembl Id: CHEMBL3827091

PubChem CID: 127045002

Max Phase: Preclinical

Molecular Formula: C33H61N11O9

Molecular Weight: 755.92

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(C)C[C@@H]1NC(=O)[C@H](CCCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)C[C@H](CO)NC1=O

Standard InChI:  InChI=1S/C33H61N11O9/c1-19(2)15-24-31(52)39-20(18-45)16-26(46)40-21(9-3-6-12-34)28(49)44-25(17-27(47)48)32(53)42-22(10-4-7-13-35)29(50)41-23(30(51)43-24)11-5-8-14-38-33(36)37/h19-25,45H,3-18,34-35H2,1-2H3,(H,39,52)(H,40,46)(H,41,50)(H,42,53)(H,43,51)(H,44,49)(H,47,48)(H4,36,37,38)/t20-,21+,22+,23+,24+,25+/m1/s1

Standard InChI Key:  PWIBEOJPRKLIKI-RFXJPFPRSA-N

Alternative Forms

  1. Parent:

    ALA3827091

    ---

Associated Targets(Human)

ADAM8 Tchem Disintegrin and metalloproteinase domain-containing protein 8 (37 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 755.92Molecular Weight (Monoisotopic): 755.4654AlogP: -3.28#Rotatable Bonds: 18
Polar Surface Area: 346.07Molecular Species: ZWITTERIONHBA: 11HBD: 13
#RO5 Violations: 3HBA (Lipinski): 20HBD (Lipinski): 16#RO5 Violations (Lipinski): 3
CX Acidic pKa: 4.08CX Basic pKa: 11.64CX LogP: -6.16CX LogD: -11.15
Aromatic Rings: 0Heavy Atoms: 53QED Weighted: 0.04Np Likeness Score: 0.88

References

1. Yim V, Noisier AF, Hung KY, Bartsch JW, Schlomann U, Brimble MA..  (2016)  Synthesis and biological evaluation of analogues of the potent ADAM8 inhibitor cyclo(RLsKDK) for the treatment of inflammatory diseases and cancer metastasis.,  24  (18): [PMID:27407033] [10.1016/j.bmc.2016.06.042]

Source